Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis

NCT04006080 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis

Interventions

BIOLOGICAL: Vedolizumab

Sponsor

Guy's and St Thomas' NHS Foundation Trust

Collaborators

[object Object]